Medicus Pharma shares rise 11.76% premarket after ringing Nasdaq Opening Bell on one-year anniversary.

Medicus Pharma (NASDAQ:MDCX) surged 11.76% in premarket trading after announcing it rang the Nasdaq Opening Bell to mark its one-year anniversary of listing. The milestone highlighted progress in advancing its clinical pipeline, including SkinJect (a $2B potential market for basal cell carcinoma) and Teverelix (a $6B combined market opportunity). The company reduced Teverelix’s royalty rate from 4% to 2%, enhancing its appeal for partnerships. Recent updates included regulatory approvals for SkinJect’s UK Phase 2 expansion and completion of 90 U.S. patients in SKNJCT-003, with topline data expected in Q1 2026. These developments underscore Medicus’ strategic focus on disciplined execution and collaboration, including a non-binding MoU with HelixNano and an AI-driven clinical data platform with Reliant AI. The Nasdaq anniversary and pipeline advancements reinforced investor confidence in the company’s growth trajectory.